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1. Introduction 
Solitary plasmacytoma (SP), histologically indistinguishable from multiple myeloma 
(MM), is a kind of malignant tumor characterized by the proliferation of monoclonal 
plasma cells. SP is an independent subtype of plasmacytoma, including extramedullary 
plasmacytoma and solitary plasmacytoma of bone (SPB) [1]. Most solitary plasmacytomas 
progress to MM, and are usually treated in the department of hematology. SPB may 
involve in any bone, however, it mainly occurs in the axial skeleton, especially in a 
vertebra. SPB has a high risk of progression to MM, and on magnetic resonance imaging 
(MRI) examination, at least 25% of patients with an apparent solitary lesion have evidence 
of disease elsewhere.  
In patients with solitary plasmacytoma of bone, the diagnosis can be made in the light of 
clinical and radiographic manifestations combined pathology. Thereafter, systemic 
treatment should be performed according to the status of the patients and the evidence of 
disease progression [2-6].  
Although definitive local radiotherapy is a choice for the treatment of SPB, no affirmative 
conclusion can be drawn due to the lack of randomized trials for this kind of disease. Surgical 
management is usually non-mandatory; however, patients may require decompression or 
reconstruction if there are spinal cord compression and pathological fracture.  
2. Epidemiology and clinical features 
SPB is a primary malignant tumor, mainly affecting axial skeleton, especially the vertebra[2]. 
These tumors occur in the spine twice as often as other bony sites [7]. The male/female ratio 
of SPB is about 2 to 1 with a mean age of 55 years [2]. Solitary plasmacytoma is one of the 
most common malignant primary tumors in spine. Involvement of the base of the skull may 
present with cranial nerve palsies. The early symptoms of SPB are not typical. The most 
common presenting symptom is pain. If spine is involved, deformity, motor deficits, sensory 
deficits, n bowel and bladder dysfunction could be seen as well as pain as result of epidural 
spinal-cord compression and/or instability of the vertebra. Plain radiography shows 
expansile, irregular osteolytic lesions with or without vertebra instability [8-9]. CT or MRI 
can detect the lesions and describe the tumor extent at an earlier stage. Particularly, MRI 
scanning has an important reference value in description of residual tumor, local relapse 
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and progression to MM after treatment [10]. The presence of M protein has been reported in 
24%-72% of patients [2]. 
3. Radiological and laboratory features 
All patients with suspected solitary plasmacytoma should undergo X-ray examination, 
computed tomography (CT) scan or magnetic resonance imaging (MRI). Plain radiographs 
showed solitary expansile osteolytic lesion with or without collapse of the vertebral body 
(Fig.A). However, plain radiographs did not show any abnormality in some patients when 
the disease was in the early stage, thus CT scan or CT three-dimensional reconstruction 
examinations were needed. Most CT scan showed osteolytic lesions with or without collapse 
of the vertebral body or even paravertebral soft tissue masses (Fig.B). As a noninvasive 
technique for detecting a potential lesion of the bone, MRI has been a routine evaluation. 
However, there are no definitive guidelines to verify the involvement on an MRI 
examination. Generally, MRI shows Low or intermediate signal on T1-weighted imaging 
and hyperintense on T2-weighted imaging, and significant enhancement with gadolinium 
(Fig.C-E). Whole-body MRI may be an effective technique to detect multiple lesions but 
costly. MRI patterns of marrow involvement play an important role in assessment myeloma 
bone disease. They include normal appearance of bone marrow despite minor microscopic 
plasma cell infiltration, focal involvement, homogeneous diffuse infiltration, combined 
diffuse and focal infiltration, and variegated or “salt-and-pepper” pattern with 
inhomogeneous bone marrow with interposition of fat islands. It is essential to have 
investigations of full skeletal survey to rule out multiple lesions. It is well-known that 
emission computed tomography (ECT) has a primary value in detecting multiple lesions of 
bone. Therefore, it is recommended for patients’ suspicion of multiple myeloma to undergo 
ECT scan, but the positive incidence of detecting occult disease is not encouraging. With the 
advent of positron emission tomography/computed tomography (PET-CT)[11-12], it is 
proved to be an important method to detect occult lesions. 
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Fig. 1. A 68-year-old man with SBP of T10. Lateral radiograph showing mild collapse of 
vertebral body height at T10 (A).Computed tomography scan showing lytic bone 
destruction of the vertebral body (B). Magnetic resonance imaging showing hypointense on 
T1-weighted imaging(C) and hyperintense on T2-weighted imaging(D), and bright 
enhancement after administration of gadolinium(E). 
If SBP is suspected, the following laboratory investigations should be performed in all patients: 
complete blood count (CBC), electrolytes, immunoglobulin, serum monoclonal paraprotein (M 
protein) electrophoresis, urine protein electrophoresis and immune fixation, marrow cell 
morphology and marrow aspiration biopsy. The prevalence of a monoclonal protein (M 
protein) in the serum or urine of patients with SBP varies from 24% to 72%, and the levels of 
the M protein(＜3g/dl) are lower than those patients with MM [2]. In our experience, marrow 
aspiration biopsy is necessary to establish the diagnosis of SBP or MM with certainty.  
4. Diagnosis  
4.1 Diagnostic criteria 
The followings are the recommended diagnostic criteria [3]: 
1. A single area of bone damage due to clonal plasma cell hyperplasia. 
2. Histologically normal marrow aspirate and trephine. 
3. Normal results on skeletal survey, including radiology of long bones. 
4. No anemia, hypercalcemia, or renal impairment due to plasma cell dyscrasia. 
5. Absent or low serum or urinary level of monoclonal immunoglobulin (level of ＞20g/L 
suspicious of MM). 
6. No additional lesions on MRI scan of the spine. 
4.2 Biopsy and pathology 
Biopsy and histopathologic examination play an important role in diagnosing this disease. 
SPB is generally diagnosed by pathology. Needle biopsy under CT or fluoroscopy guidance 
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can be safe and effective. As this kind of tumor is rare, it is recommended that pathology 
review should be performed by a senior histopathologist who is skilled in bone tumor or 
lymphatic system diseases. In our experience, the definitive diagnosis of SPB should be 
based on clinical, radiologic, and pathologic findings of patients. 
5. Treatment of solitary plasmacytoma of bone 
5.1 Radiotherapy and recommendations 
Radiotherapy is considered the treatment of choice for solitary plasmacytoma of bone. 
Although high local control rates of 83% to 96% are achieved with moderate doses of 
radiotherapy, the progression to multiple myeloma is considerably common [6,13-17]. 
However, the evidence base of radiotherapy is largely consisted of retrospective studies of 
small series of patients. In addition, data on dose-response relationships are weak in most 
series of the literatures [3]. 
On the basis of evidences in the literatures, recommendations were put forward by 
oncologists [3,5,6]. The recommendation on the dose of radiotherapy is 40Gy in 20 fractions 
for lesions with a margin of at least 2 centimeters. For lesions of SPB greater than 5 
centimeters, a higher dose of up to 50Gy in 25 fractions should be considered. As for the 
extent of radiation management, the clinical target volume should include the tumor shown 
on MRI with a margin of at least 2 cm. For a vertebral lesion, the scope of radiotherapy 
should cover the entire bone involved, together with uninvolved adjacent vertebrae [3,8,18]. 
For solitary plasmacytoma of spine, considering the anatomical specificity, more exact 
measurement of radiotherapy dose and target volume is needed to avoid unnecessary 
irritation or damage of normal tissues and neurological elements. It should include the 
whole involved vertebra, together with one uninvolved vertebra above and below. 
5.2 Surgery and recommendations 
Surgery is not the first choice to treat solitary plasmacytoma of bone. However, it remains a 
reliable option for patients with intractable pain as a result of the vertebral involvement, 
vertebral instability, neurological compromise, or a combination of these disorders [3,8,9,19]. 
It is the only method that leads to immediate relief of spinal compression and direct 
biomechanical stabilization of the involved vertebra. Indications for surgery include 
[3,8,9,19,20]: any patient with an unstable of spine where surgery is the only way to fix and 
reconstruct the stabilization of spine; malignant spinal cord compression which can be 
alleviated by surgery; direct compression by intraspinal bony fragments; existing or 
impending motor dysfunction for which immediate decompression is required; no response 
to radiotherapy or radiotherapy tolerance and disease progressing.  
The choice of surgical methods depends on the site and extent of the tumor, general 
condition of each patient, as well as skills and experience of surgeons. It is required that 
surgical plan should be designed carefully before procedure [21,22]. A gross-total resection 
is a reasonable choice for cervical spine tumor [23], and total en-bloc resection is feasible but 
challenging [22,24]. However, total en-bloc spondylectomy or resection is ideal for lesions in 
thoracic and lumbar spine and extraspinal involvements [22,24-26]. Given to the probability 
of long-term survival in patients with this disease, it is recommended that reconstruction of 
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the involved spine should be performed [2,8,27]. For extraspinal osseous lesion, definitive 
local radiotherapy is the main treatment method. However, if pathological fractures of long 
bones or weight-bearing bones have been detected, surgical resection and fixation may also 
be required.  
If surgery is required, radiotherapy should also be given. However, surgery should be 
carried out before radiotherapy because surgery may become more difficult in patients with 
preoperative radiotherapy [2,8,28,29]. Spinal radiation before surgery is associated with a 
significantly higher rate of major wound complication and may adversely affect the surgical 
outcome [28]. 
5.3 Chemotherapy and recommendations 
Although there are insufficient data to support and advocate adjuvant chemotherapy for 
patients with SBP, it may be appropriate to consider to adjuvant radiotherapy in patients at 
higher risk of treatment failure [2-5]. Aviles et al [30] performed a prospective study which 
reported a benefit with combined chemotherapy and RT compared to RT alone. This study 
concluded that combined radiochemotherapy were likely to increase remission and survival 
duration. A suggested approach is to follow guidelines for the treatment of multiple 
myeloma [3]. In addition, patients presenting as SBP, but found on MRI to have more 
extensive disease, should be considered as having MM and treated accordingly [2,3,6]. In 
addition, bisphosphonate treatment lasting for at least one year may be benefit for patients 
with SBP. As for patients with MM, the bisphosphonate treatment should be prolonged to 2 
years. Such management can be effective in reducing skeletal-related events [3,31-33]. 
6. Natural history and prognosis 
The general prognosis of SP is comparatively better, with a 5-year survival rate about 70% 
and median overall survival period of 7.5-12 years [2,3,34]. There is no clear factor to predict 
prognosis of SP. Some researchers consider the following factors as prognosis [3,5,17,18]: old 
age, tumor size, and persistence of M protein after treatment. Majority of patients probably 
developed MM in the end with the median time of 2-4 years, especially those with SP of 
spine [5,15,16-18], and approximately 15%-45% of patients remain disease free at 10 years[4].  
However, there is still no effective method to prevent SPB from progressing to MM and 
there is no consensus in the literature about these adverse prognostic features. Wilder et 
al[36]performed a multivariate analysis on prognostic factors in a series of 60 patients and 
considered sustained M protein for over one year after radiotherapy as the adverse 
prognostic factor, while age, tumor size and paraprotein level were of no special prognostic 
value. Modalities for monitoring of disease status such as PET/CT, free light chain 
examination, marrow aspiration biopsy, etc. could identify high risk groups for disease 
progression [3,5,6,11,12]. 
For patients with SBP, it is required carefully monitoring to detect progression to MM, 
possibly 6 weekly for 6 months, with extension of clinic appointments. Assessment of signs 
and symptoms should be undertaken, together with radiographic and laboratory 
investigations such as MRI, haematology, biochemistry, serum and urine paraprotein 
estimation [2-6,14].  
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